Nice

News

NICE rejects J&J's prostate cancer drug Erleada in initial g...

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance.

News

NICE says final 'no' to BMS' Zeposia for multiple sclerosis

NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and Wales.

Views & Analysis

How will NICE fare in a post-Brexit world?

NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU?

News

NICE says 'no' to Pfizer's Vyndaqel for rare heart condition

NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if the pharma decid

News

Solving the elective care conundrum through digital innovation

NICE's Office for Digital Health opens its doors

UK cost-effectiveness agency NICE has this week officially opened the Office for Digital Health, one of the pillars of its five-year strategy out to 2026.

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

Patients in England get fast access to AZ's Tagrisso in earl...

The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early stage lung cancer, with NICE allowing fast access to patients on E

NICE rejects J&J's prostate cancer drug Erleada in initial g...

NICE says final 'no' to BMS' Zeposia for multiple sclerosis

How will NICE fare in a post-Brexit world?

NICE says 'no' to Pfizer's Vyndaqel for rare heart condition

NICE's Office for Digital Health opens its doors

Patients in England get fast access to AZ's Tagrisso in earl...

On AI and computational support of biochemistry, with Alan R...

The AI imperative: Establishing the standard for modern clin...

Nice

Editor's Picks